Zoetis (ZOTS) Stock Overview
Engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
ZOTS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Zoetis Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$65.96 |
| 52 Week High | US$136.00 |
| 52 Week Low | US$62.08 |
| Beta | 0.73 |
| 1 Month Change | -0.42% |
| 3 Month Change | -2.94% |
| 1 Year Change | -51.26% |
| 3 Year Change | -60.92% |
| 5 Year Change | -62.07% |
| Change since IPO | -41.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZOTS | AT Pharmaceuticals | AT Market | |
|---|---|---|---|
| 7D | 5.4% | -1.1% | -0.07% |
| 1Y | -51.3% | 13.7% | 27.3% |
Return vs Industry: ZOTS underperformed the Austrian Pharmaceuticals industry which returned 13.7% over the past year.
Return vs Market: ZOTS underperformed the Austrian Market which returned 27.3% over the past year.
Price Volatility
| ZOTS volatility | |
|---|---|
| ZOTS Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in AT Market | 9.4% |
| 10% least volatile stocks in AT Market | 2.7% |
Stable Share Price: ZOTS has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: ZOTS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 14,500 | Kristin Peck | www.zoetis.com |
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics.
Zoetis Inc. Fundamentals Summary
| ZOTS fundamental statistics | |
|---|---|
| Market cap | €26.21b |
| Earnings (TTM) | €2.26b |
| Revenue (TTM) | €8.17b |
Is ZOTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZOTS income statement (TTM) | |
|---|---|
| Revenue | US$9.53b |
| Cost of Revenue | US$2.69b |
| Gross Profit | US$6.83b |
| Other Expenses | US$4.20b |
| Earnings | US$2.64b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.38 |
| Gross Margin | 71.74% |
| Net Profit Margin | 27.69% |
| Debt/Equity Ratio | 288.0% |
How did ZOTS perform over the long term?
See historical performance and comparisonDividends
Does ZOTS pay a reliable dividends?
See ZOTS dividend history and benchmarks| Zoetis dividend dates | |
|---|---|
| Ex Dividend Date | Jul 20 2026 |
| Dividend Pay Date | Sep 01 2026 |
| Days until Ex dividend | 31 days |
| Days until Dividend pay date | 12 days |
Does ZOTS pay a reliable dividends?
See ZOTS dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/19 19:26 |
| End of Day Share Price | 2026/08/19 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zoetis Inc. is covered by 39 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Charles Butler | Barclays |
| Glen Santangelo | Barclays |